Cancers, Free Full-Text

Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers. However, XPO1 biology and selinexor sensitivity in childhood cancer is only recently being explored. In this review, we will focus on the differential biology of childhood and adult cancers as it relates to XPO1 and key cargo proteins. We will further explore the current state of pre-clinical and clinical development of XPO1 inhibitors in childhood cancers. Finally, we will outline potentially promising future therapeutic strategies for, as well as potential challenges to, integrating XPO1 inhibition to improve outcomes for children with cancer.

The autophagic paradox in cancer therapy

Patch Para Alh Get File - Colaboratory

Cancers, Free Full-Text

Cancer treatment and survivorship statistics, 2022 - Miller - 2022

Multimodal analysis of methylomics and fragmentomics in plasma

PDF) Late Stage Cervical Cancer among Confirmed Cervical Cancer

Multimodal analysis of cell-free DNA whole-methylome sequencing

The global burden of cancer attributable to risk factors, 2010–19

Cancer burden among adolescents and young adults in relation to

Event-free Survival with Pembrolizumab in Early Triple-Negative

Hypercalcemia and treated breast cancers: The diagnostic dilemma